Swanson Reed News

ATO Release First R&D Tax Incentive Transparency Reporting Data

October 8th, 2024

As now required by law, The Australian Taxation Office (ATO) has released its first annual Research and Development (R&D) tax transparency report on entities claiming the R&D tax offset. The information the ATO published includes: name of the R&D entity claiming the R&D tax incentive and their ABN/ACN; entity’s total expenditure on R&D (known as total notional deductions claimed – label Z in Part A of the R&D tax incentive schedule) less any feedstock adjustments (label B in Part B […]

Read More

R&D Tax Registrations – Deadline this month

October 1st, 2024

Companies seeking to register R&D Activities conducted during the Year Ended 31 December 2023 (companies that have a December Year End for tax) who are yet to do so should note that the Registration Deadline is the end of October 2024. The extensions granted during COVID no longer apply, and the statutory deadlines revert to normal (10 months after the end of a company’s financial year). There are mechanisms available under the IR&D Act and IRD Decision making provisions that allow for […]

Read More

‘Made in Queensland’ Round 7 Grant Applications

September 23rd, 2024

The Queensland Government has announced that Round 7 grant applications for their Made in Queensland (MIQ) Grant will open on September 24th.   MIQ offers grants up to $2.5 million for Queensland small to medium manufacturers. The program is designed to help manufacturers increase their international competitiveness, productivity and innovation, and generate high-skilled jobs for the future by purchasing and implementing new and advanced equipment or technologies as part of operations. Whilst companies that can attain grant funding should look […]

Read More

Telix Pharmaceuticals solidifies Australian Biotech Success, posting net profit after years of Refundable R&D Tax Offset Recipients

September 16th, 2024

Melbourne-based Telix Pharmaceuticals has previously been one of the largest recipients of the R&D Tax incentive, and has continued its rare feat in Biotechnology; commercialising a product, and progressing to growth and profit. The company’s radiopharmaceuticals are designed to deliver focused doses of radiation with precision targeting via an injection, regardless of where the cancer or disease is in the body. In the early stages of Telix Pharmaceuticals, the company was receiving substantial refundable R&D Tax Offsets (including more than $12M […]

Read More

Alex Chisholm
Principal, Melbourne
Tom Parkhouse
Principal, Sydney
Andy Nguyen
Principal, Brisbane
Holly Parkinson
Manager, Adelaide
David Greatwich
Principal, Perth
Krishna Gungaram
Manager, Hobart

Categories

Archives